{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:10:09Z","timestamp":1770297009940,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lipella Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hemorrhagic cystitis (HC) is an inflammatory disease of the bladder with sustained hematuria for which there is currently no approved drug treatment. We evaluated a liposomal tacrolimus preparation (LP-10) in patients with refractory moderate to severe sterile HC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This phase 2a dose-escalation study assessed the safety and efficacy of up to 2\u00a0intravesical instillations of LP-10 (2, 4, or 8\u00a0mg tacrolimus) in 13 patients with HC. Primary efficacy outcomes were changes from baseline in the number of bleeding sites on cystoscopy, microscopic urine analysis for red blood cells (RBCs), and hematuria on dipstick. Additional efficacy measures included urinary incontinence, frequency, and urgency on a 3-day diary and cystoscopy global response assessment (GRA). Blood samples for pharmacokinetic (PK) assessment were obtained in all patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Intravesical LP-10 was well tolerated, with no treatment-related severe or serious adverse events (AEs) and only 3 drug-related AEs (artificial urinary sphincter malfunction, dysuria, and bladder spasms). LP-10 blood levels showed short durations of minimal systemic uptake. Treatment resulted in significant improvements in bleeding on cystoscopy, RBC counts in urine, hematuria on dipstick, and urinary incontinence. Bleeding on cystoscopy and urinary incontinence showed dose-dependent improvements that were more pronounced in the 4\u00a0mg and 8\u00a0mg dose groups. All dose groups showed a significant improvement in cystoscopy GRA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>LP-10 was well tolerated, with clinically relevant efficacy seen in improvements in cystoscopic bleeding, hematuria, and urinary incontinence. The benefit-risk profile supports the further clinical development of LP-10 at a tacrolimus dose of 4\u00a0mg.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11255-023-03783-y","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T09:02:58Z","timestamp":1695114178000},"page":"87-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study"],"prefix":"10.1007","volume":"56","author":[{"given":"Jason","family":"Hafron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin N.","family":"Breyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreyas","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa R.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Okonski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-8972","authenticated-orcid":false,"given":"Michael B.","family":"Chancellor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"issue":"10","key":"3783_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/J.Bbmt.2005.06.007","volume":"11","author":"E Gorczynska","year":"2005","unstructured":"Gorczynska E, Turkiewicz D, Rybka K et al (2005) Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 11(10):797\u2013804. https:\/\/doi.org\/10.1016\/J.Bbmt.2005.06.007","journal-title":"Biol Blood Marrow Transplant"},{"key":"3783_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/Biology11070972","author":"C Brossard","year":"2022","unstructured":"Brossard C, Lefranc A-C, Pouliet A-L et al (2022) Molecular mechanisms and key processes in interstitial hemorrhagic and radiation cystitis. Biology. https:\/\/doi.org\/10.3390\/Biology11070972","journal-title":"Biology"},{"issue":"7","key":"3783_CR3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/Bju.12291","volume":"112","author":"H Payne","year":"2013","unstructured":"Payne H, Adamson A, Bahl A et al (2013) Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges. BJU Int 112(7):885\u2013897. https:\/\/doi.org\/10.1111\/Bju.12291","journal-title":"BJU Int"},{"issue":"1","key":"3783_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2051415813512647","volume":"7","author":"A Thompson","year":"2014","unstructured":"Thompson A, Adamson A, Bahl A et al (2014) Guidelines for the diagnosis, prevention and management of chemical- and radiation-induced cystitis. J Clin Urol 7(1):25\u201335. https:\/\/doi.org\/10.1177\/2051415813512647","journal-title":"J Clin Urol"},{"issue":"6","key":"3783_CR5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/J.Juro.2014.06.030","volume":"192","author":"L Bj","year":"2014","unstructured":"Bj L, Rf T, Sa B (2014) Cystectomy for refractory hemorrhagic cystitis: contemporary etiology, presentation and outcomes. J Urol 192(6):1687\u20131692. https:\/\/doi.org\/10.1016\/J.Juro.2014.06.030","journal-title":"J Urol"},{"issue":"3","key":"3783_CR6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/0090-4295(82)90633-1","volume":"20","author":"D Mj","year":"1982","unstructured":"Mj D, Saral R, Santos G (1982) Prevention of cyclophosphamide-induced hemorrhagic cystitis. Urology 20(3):256\u2013258. https:\/\/doi.org\/10.1016\/0090-4295(82)90633-1","journal-title":"Urology"},{"issue":"5","key":"3783_CR7","first-page":"11276","volume":"29","author":"D Mj","year":"2022","unstructured":"Mj D, Foss H, Uhr A et al (2022) Hemorrhagic cystitis: a review of the literature and treatment options. Can J Urol 29(5):11276\u201311283","journal-title":"Can J Urol"},{"issue":"3","key":"3783_CR8","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/S0041-1345(01)01994-7","volume":"33","author":"K Migita","year":"2001","unstructured":"Migita K, Eguchi K (2001) Fk 506-mediated T cell apoptosis induction. Transpl Proc 33(3):2292\u20132293. https:\/\/doi.org\/10.1016\/S0041-1345(01)01994-7","journal-title":"Transpl Proc"},{"key":"3783_CR9","unstructured":"Astellas Pharma US, Inc. Prograf (tacrolimus) [package insert]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/050708s054,050709s047,204096s010lbl.pdf. Revised November 2022. Accessed 13 Sept 2023"},{"key":"3783_CR10","unstructured":"Astellas Pharma US. Protopic (tacrolimus) [package insert]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050777s018lbl.pdf. Revised November 2011. Accessed 13 Sept 2023"},{"issue":"3","key":"3783_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5301\/Jn.5000174","volume":"25","author":"EJ Hoorn","year":"2012","unstructured":"Hoorn EJ, Walsh SB, Mccormick JA et al (2012) Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 25(3):269\u2013275. https:\/\/doi.org\/10.5301\/Jn.5000174","journal-title":"J Nephrol"},{"issue":"2","key":"3783_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/Cjn.04800908","volume":"4","author":"M Naesens","year":"2009","unstructured":"Naesens M, Drj K, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol CJASN 4(2):481\u2013508. https:\/\/doi.org\/10.2215\/Cjn.04800908","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"3","key":"3783_CR13","first-page":"191","volume":"23","author":"MJ Rico","year":"2002","unstructured":"Rico MJ, Lawrence I (2002) Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacologic effects. Allergy Asthma Proc 23(3):191\u2013197","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"3783_CR14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/J.Eururo.2008.03.013","volume":"54","author":"AK Ebert","year":"2008","unstructured":"Ebert AK, R\u00f6sch WH, Vogt T (2008) Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study. Eur Urol 54(4):932\u2013937. https:\/\/doi.org\/10.1016\/J.Eururo.2008.03.013","journal-title":"Eur Urol"},{"key":"3783_CR15","doi-asserted-by":"publisher","first-page":"CD009864","DOI":"10.1002\/14651858.Cd009864.Pub2","volume":"2015","author":"J Cury Martins","year":"2015","unstructured":"Cury Martins J, Martins C, Aoki V et al (2015) Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev 2015:CD009864. https:\/\/doi.org\/10.1002\/14651858.Cd009864.Pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3783_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4103\/2230-973x.106981","volume":"2","author":"P Patel","year":"2012","unstructured":"Patel P, Patel H, Panchal S et al (2012) Formulation strategies for drug delivery of tacrolimus: an overview. Int J Pharma Investig 2(4):169\u2013175. https:\/\/doi.org\/10.4103\/2230-973x.106981","journal-title":"Int J Pharma Investig"},{"issue":"3","key":"3783_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/Nau.20981","volume":"30","author":"Y-C Chuang","year":"2011","unstructured":"Chuang Y-C, Tyagi P, Huang H-Y et al (2011) Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. Neurourol Urodyn 30(3):421\u2013427. https:\/\/doi.org\/10.1002\/Nau.20981","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"3783_CR18","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/J.Juro.2012.10.123","volume":"189","author":"J Nirmal","year":"2013","unstructured":"Nirmal J, Tyagi P, Chancellor MB et al (2013) Development of potential orphan drug therapy of intravesical liposomal tacrolimus for hemorrhagic cystitis due to increased local drug exposure. J Urol 189(4):1553\u20131558. https:\/\/doi.org\/10.1016\/J.Juro.2012.10.123","journal-title":"J Urol"},{"issue":"2","key":"3783_CR19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/J.Juro.2015.03.108","volume":"194","author":"BR Rajaganapathy","year":"2015","unstructured":"Rajaganapathy BR, Janicki JJ, Levanovich P et al (2015) Intravesical liposomal tacrolimus protects against radiation cystitis induced by 3-beam targeted bladder radiation. J Urol 194(2):578\u2013584. https:\/\/doi.org\/10.1016\/J.Juro.2015.03.108","journal-title":"J Urol"},{"issue":"2","key":"3783_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/Nau.1930140206","volume":"14","author":"JS Uebersax","year":"1995","unstructured":"Uebersax JS, Wyman JF, Shumaker SA et al (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the incontinence impact questionnaire and the urogenital distress inventory. Continence Program For Women Research Group. Neurourol Urodyn 14(2):131\u2013139. https:\/\/doi.org\/10.1002\/Nau.1930140206","journal-title":"Neurourol Urodyn"},{"key":"3783_CR21","unstructured":"Euroqol Eq-5d-3l. https:\/\/www.euroqol.org\/"},{"issue":"2","key":"3783_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.25259\/Ijdvl_1229_20","volume":"88","author":"S Baveja","year":"2022","unstructured":"Baveja S, Neema S, Pathania V et al (2022) Tacrolimus as a therapeutic alternative in psoriasis: a retrospective observational study. Indian J Dermatol Venereol Leprol 88(2):247\u2013249. https:\/\/doi.org\/10.25259\/Ijdvl_1229_20","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"3783_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2478\/Rir-2022-0034","volume":"3","author":"S Chen","year":"2022","unstructured":"Chen S, Liao P, Xi L et al (2022) The therapeutic effect of tacrolimus in a mouse psoriatic model is associated with the induction of myeloid-derived suppressor cells. Rheumatol Immunol Res 3(4):190\u2013197. https:\/\/doi.org\/10.2478\/Rir-2022-0034","journal-title":"Rheumatol Immunol Res"},{"issue":"6","key":"3783_CR24","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1046\/J.1365-2133.2002.04800.X","volume":"146","author":"M Erdogan","year":"2002","unstructured":"Erdogan M, Wright JR, Mcalister VC (2002) Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Brit J Dermatol 146(6):964\u2013967. https:\/\/doi.org\/10.1046\/J.1365-2133.2002.04800.X","journal-title":"Brit J Dermatol"},{"issue":"9","key":"3783_CR25","first-page":"545","volume":"20","author":"JQ Del Rosso","year":"2007","unstructured":"Del Rosso JQ, Conte ET (2007) An investigator-blinded evaluation of fluocinonide 0.1% cream in the treatment of atopic dermatitis and psoriasis vulgaris. Cosmet Dermatol 20(9):545\u2013552","journal-title":"Cosmet Dermatol"},{"issue":"8","key":"3783_CR26","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/Jamadermatol.2019.0696","volume":"155","author":"JH Lee","year":"2019","unstructured":"Lee JH, Kwon HS, Jung HM et al (2019) Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol 155(8):929\u2013938. https:\/\/doi.org\/10.1001\/Jamadermatol.2019.0696","journal-title":"JAMA Dermatol"},{"issue":"12","key":"3783_CR27","doi-asserted-by":"publisher","first-page":"E11985","DOI":"10.7759\/Cureus.11985","volume":"12","author":"H Mumtaz","year":"2020","unstructured":"Mumtaz H, Anis S, Akhtar A et al (2020) Efficacy of tacrolimus versus clobetasol in the treatment of vitiligo. Cureus 12(12):E11985. https:\/\/doi.org\/10.7759\/Cureus.11985","journal-title":"Cureus"},{"issue":"7","key":"3783_CR28","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/J.Jid.2020.12.028","volume":"141","author":"J Seneschal","year":"2021","unstructured":"Seneschal J, Duplaine A, Maillard H et al (2021) Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study. J Investig Dermatol 141(7):1728\u20131734. https:\/\/doi.org\/10.1016\/J.Jid.2020.12.028","journal-title":"J Investig Dermatol"},{"issue":"1","key":"3783_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/S12903-022-02168-4","volume":"22","author":"S Sandhu","year":"2022","unstructured":"Sandhu S, Klein BA, Al-Hadlaq M et al (2022) Oral lichen planus: comparative efficacy and treatment costs-a systematic review. BMC Oral Health 22(1):161. https:\/\/doi.org\/10.1186\/S12903-022-02168-4","journal-title":"BMC Oral Health"},{"issue":"12","key":"3783_CR30","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1111\/Jdv.18457","volume":"36","author":"S Utz","year":"2022","unstructured":"Utz S, Suter VGA, Cazzaniga S et al (2022) Outcome and long-term treatment protocol for topical tacrolimus in oral lichen planus. J Eur Acad Dermatol Venereol JEADV 36(12):2459\u20132465. https:\/\/doi.org\/10.1111\/Jdv.18457","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"6","key":"3783_CR31","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.4103\/Ijo.Ijo_1971_20","volume":"69","author":"A Mohanty","year":"2021","unstructured":"Mohanty A, Mitra S, Mallick A et al (2021) Sequelae of microsporidial keratoconjunctivitis and its management. Indian J Ophthalmol 69(6):1537\u20131543. https:\/\/doi.org\/10.4103\/Ijo.Ijo_1971_20","journal-title":"Indian J Ophthalmol"},{"key":"3783_CR32","doi-asserted-by":"publisher","first-page":"100582","DOI":"10.1016\/J.Ajoc.2019.100582","volume":"17","author":"SS Shoughy","year":"2020","unstructured":"Shoughy SS, Aljassar FM, Tabbara KF (2020) Aqueous penetration of topical tacrolimus. Am J Ophthalmol Case Rep 17:100582. https:\/\/doi.org\/10.1016\/J.Ajoc.2019.100582","journal-title":"Am J Ophthalmol Case Rep"},{"key":"3783_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/Jim-2020-001699","author":"G Salem","year":"2021","unstructured":"Salem G, Ding K, Sakuraba A et al (2021) Role of topical tacrolimus in the management of proctitis, perianal manifestations in Crohn\u2019s disease and chronic pouchitis: a systematic review. J Investig Med. https:\/\/doi.org\/10.1136\/Jim-2020-001699","journal-title":"J Investig Med"},{"issue":"13","key":"3783_CR34","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3748\/Wjg.V25.I13.1603","volume":"25","author":"P Hoffmann","year":"2019","unstructured":"Hoffmann P, Wehling C, Krisam J et al (2019) Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World J Gastroenterol 25(13):1603\u20131617. https:\/\/doi.org\/10.3748\/Wjg.V25.I13.1603","journal-title":"World J Gastroenterol"},{"key":"3783_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16140","author":"KD Li","year":"2023","unstructured":"Li KD, Jones CP, Hakam N, Erickson BA, Vanni AJ, Chancellor MB, Breyer BN (2023) Haemorrhagic cystitis: a review of management strategies and emerging treatments. BJU Int. https:\/\/doi.org\/10.1111\/bju.16140","journal-title":"BJU Int"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03783-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03783-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03783-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T16:17:46Z","timestamp":1704817066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03783-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["3783"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03783-y","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"16 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JO and MC are affiliated with Lipella Pharmaceuticals as employees. All other authors have no competing interests to declare, except for their roles as trial investigators.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}